Activity and acceptability of piribedil in Parkinson's disease: a multicentre study - PubMed (original) (raw)
Clinical Trial
. 1992:239 Suppl 1:S28-34.
doi: 10.1007/BF00819564.
Affiliations
- PMID: 1634909
- DOI: 10.1007/BF00819564
Clinical Trial
Activity and acceptability of piribedil in Parkinson's disease: a multicentre study
P Rondot et al. J Neurol. 1992.
Abstract
Several controlled trials have shown that the dopamine agonist, Trivastal (piribedil), is active in the treatment of Parkinson's disease, particularly with regard to tremor. To determine its efficacy as monotherapy in patients previously untreated with levodopa, a 3-month multicentre study was conducted with Trivastal 50 mg LP in 113 patients with idiopathic Parkinson's disease. The study population consisted of 66 men and 47 women, aged 63.1, SD 0.6 (43-79) years with a 2.1, SD 0.2 (1-15) year history of Parkinson's disease. Mean disease stage was 1.82 (1-4) by the Hoehn and Yahr classification. Tremor was the predominant clinical feature in 42 patients; the remaining 71 patients displayed the full parkinsonian syndrom. Trivastal 50 mg LP was prescribed stepwise up to doses of 150-250 (207, SD 6.4) mg/day at the end of 3 months. No concomitant anti-parkinsonian medication was given. Patients were clinically assessed at 1, 2 and 3 months on the Webster scale, a specific tremor scale and the HARD depression scale. Mean results were as follows in the 90 patients completing the study. On the Webster scale, tremor fell from 1.7 to 1 (-41%, P less than 0.001), bradykinesia from 1.5 to 0.8 (-47%, P less than 0.001) and rigidity from 1.3 to 0.9 (-31%, P less than 0.001); on the specific scale, rest tremor decreased in daily duration and amplitude from 3.9 to 2.4 (-39%, P less than 0.001) and from 2.9 to 2.1 (-35%, P less than 0.001), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- [Action of piribedil in Parkinson disease. Multicenter study].
Ziégler M, Rondot P. Ziégler M, et al. Presse Med. 1999 Sep 11;28(26):1414-8. Presse Med. 1999. PMID: 10518963 Clinical Trial. French. - [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G, Wix Ramos R, Salazar Aladrén P, Jiménez León JC. Salazar Tortolero G, et al. Rev Neurol. 2004 Apr 16-30;38(8):715-9. Rev Neurol. 2004. PMID: 15122540 Clinical Trial. Spanish. - Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, Bundhukul A. Suwantamee J, et al. J Med Assoc Thai. 2004 Nov;87(11):1293-300. J Med Assoc Thai. 2004. PMID: 15825702 Clinical Trial. - Parkinson's disease: pathological mechanisms and actions of piribedil.
Jenner P. Jenner P. J Neurol. 1992;239 Suppl 1:S2-8. doi: 10.1007/BF00819559. J Neurol. 1992. PMID: 1634907 Review. - [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
Pilipovich AA, Golubev VL. Pilipovich AA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(6):83-90. doi: 10.17116/jnevro20171176183-90. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28745677 Review. Russian.
Cited by
- Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
Gallagher DA, Schrag A. Gallagher DA, et al. CNS Drugs. 2008;22(7):563-86. doi: 10.2165/00023210-200822070-00003. CNS Drugs. 2008. PMID: 18547126 Review. - Current status of dopamine agonists in Parkinson's disease management.
Montastruc JL, Rascol O, Senard JM. Montastruc JL, et al. Drugs. 1993 Sep;46(3):384-393. doi: 10.2165/00003495-199346030-00005. Drugs. 1993. PMID: 7693430 Review. - Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.
Perez-Lloret S, Rascol O. Perez-Lloret S, et al. CNS Drugs. 2016 Aug;30(8):703-17. doi: 10.1007/s40263-016-0360-5. CNS Drugs. 2016. PMID: 27344665 Review. - 2-{4-[(1,3-Benzodioxol-5-yl)meth-yl]piperazin-1-yl}pyrimidine.
Wu C, Li J, Wei H, Hang Y, Jiang Y. Wu C, et al. Acta Crystallogr Sect E Struct Rep Online. 2013 Jun 22;69(Pt 7):o1140. doi: 10.1107/S1600536813016851. eCollection 2013. Acta Crystallogr Sect E Struct Rep Online. 2013. PMID: 24046690 Free PMC article. - Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology.
Borovac JA. Borovac JA. Yale J Biol Med. 2016 Mar 24;89(1):37-47. eCollection 2016 Mar. Yale J Biol Med. 2016. PMID: 27505015 Free PMC article. Review.
References
- Neurology. 1967 May;17(5):427-42 - PubMed
- Neuroendocrinology. 1975;19(3):227-40 - PubMed
- J Pharm Pharmacol. 1971 Dec;23(12):989-91 - PubMed
- Eur J Pharmacol. 1972 Nov;20(2):195-204 - PubMed
- Arch Neurol. 1974 May;30(5):383-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical